Natixis Advisors
RARE icon

Natixis Advisors’s Ultragenyx Pharmaceutical RARE Stock Holding History

Natixis Advisors’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$711K Buy
21,296
+5,970
+39% +$148K ﹤0.01% 1601
2026
Q1 		$321K Sell
15,326
-5,751
-27% -$130K ﹤0.01% 1638
2025
Q4 		$485K Buy
21,077
+1,498
+8% +$49.3K ﹤0.01% 1451
2025
Q3 		$589K Sell
19,579
-27,290
-58% -$818K ﹤0.01% 1448
2025
Q2 		$1.7M Buy
46,869
+23,363
+99% +$842K ﹤0.01% 1138
2025
Q1 		$851K Sell
23,506
-27,404
-54% -$1.14M ﹤0.01% 1317
2024
Q4 		$2.14M Sell
50,910
-1,652
-3% -$82K ﹤0.01% 1075
2024
Q3 		$2.92M Buy
52,562
+39,086
+290% +$1.99M 0.01% 977
2024
Q2 		$554K Sell
13,476
-218
-2% -$9.31K ﹤0.01% 1413
2024
Q1 		$639K Sell
13,694
-1,595
-10% -$75.2K ﹤0.01% 1333
2023
Q4 		$731K Buy
15,289
+1,496
+11% +$58K ﹤0.01% 1302
2023
Q3 		$492K Sell
13,793
-1,957
-12% -$77.5K ﹤0.01% 1361
2023
Q2 		$727K Buy
15,750
+4,492
+40% +$208K ﹤0.01% 1242
2023
Q1 		$451K Buy
11,258
+1,016
+10% +$43.6K ﹤0.01% 1331
2022
Q4 		$475K Buy
+10,242
New +$403K ﹤0.01% 1304

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Natixis Advisors's RARE Position: Q2 2026 in Review

Natixis Advisors increased its Ultragenyx Pharmaceutical (RARE) stake by 39% in Q2 2026, buying an estimated $148K and bringing the position to 21,296 shares worth $711K. The position accounts for ﹤0.01% of the portfolio, ranked #1601.

Natixis Advisors first reported a position in RARE in Q4 2022 and has held it in 15 quarters since. The position peaked at $2.92M in Q3 2024. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Natixis Advisors held 21,296 shares of Ultragenyx Pharmaceutical worth $711K as of Q2 2026.
  • Natixis Advisors bought 5,970 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $148K.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Natixis Advisors's portfolio in Q2 2026, its #1601 holding.
  • Natixis Advisors first reported a position in Ultragenyx Pharmaceutical in Q4 2022 and has held it in 15 quarters since.
  • Natixis Advisors's Ultragenyx Pharmaceutical position peaked at $2.92M in Q3 2024.
  • 311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Natixis Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.